文献速递基础与转化研究临床试验与 GCP新药、器械与细胞基因治疗研发

Exagamglogene Autotemcel 治疗输血依赖型β地中海贫血

Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
PubMed 文献 · N Engl J Med · 2024-04-24

这项开放标签、单组、3期研究评估了exa-cel(经CRISPR-Cas9编辑BCL11A红系增强子的自体CD34+造血干/祖细胞)在12至35岁输血依赖型β地中海贫血患者中的疗效。52例患者接受exa-cel,中位随访20.4个月;在35例有足够随访数据的患者中,32例(91%;95%CI 77至98;P<0.001)达到输血独立。结论认为,经清髓预处理后,exa-cel治疗使91%的输血依赖型β地中海贫血患者获得输血独立。

要点

  • 在35例可评估患者中,32例(91%;95%CI 77至98;P<0.001)达到输血独立。
  • 输血独立期间,平均总血红蛋白为13.1 g/dL,平均胎儿血红蛋白为11.9 g/dL。
  • 安全性总体与清髓性白消安预处理和自体造血干/祖细胞移植一致,无死亡或癌症发生。

核心结论

  • 经清髓预处理后,exa-cel治疗使91%的输血依赖型β地中海贫血患者获得输血独立。

研究设计与样本

  • 开放标签、单组、3期研究,纳入12至35岁输血依赖型β地中海贫血且基因型为β0/β0、β0/β0样或非β0/β0样的患者。
  • 共52例患者接受exa-cel并纳入预设中期分析,中位随访20.4个月(范围2.1至48.1)。
  • CD34+造血干/祖细胞经CRISPR-Cas9和向导mRNA编辑,输注前接受药代动力学剂量调整的白消安清髓预处理。
  • 主要终点为输血独立,定义为连续至少12个月不输红细胞且血红蛋白加权平均值≥9 g/dL。

主要发现

  • 在35例有足够随访数据的患者中,32例(91%;95%CI 77至98;P<0.001,对照50%应答的无效假设)达到输血独立。
  • 每例患者的中性粒细胞和血小板均成功植入。
  • 输血独立期间,平均总血红蛋白为13.1 g/dL,平均胎儿血红蛋白为11.9 g/dL,胎儿血红蛋白呈全细胞分布(≥94%的红细胞)。
  • 安全性特征总体与清髓性白消安预处理和自体造血干/祖细胞移植一致,无死亡或癌症发生。

关键数值与推荐

  • 主要终点输血独立:连续至少12个月不输红细胞且血红蛋白加权平均值≥9 g/dL。
  • 在35例可评估患者中,32例(91%;95%CI 77至98;P<0.001)达到输血独立。
  • 输血独立期间平均总血红蛋白13.1 g/dL,平均胎儿血红蛋白11.9 g/dL,胎儿血红蛋白全细胞分布≥94%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 gene editing of the erythroid-specific enhancer region of BCL11A in autologous CD34+ hematopoietic stem and progenitor cells (HSPCs). METHODS: We conducted an open-label, single-group, phase 3 study of exa-cel in patients 12 to 35 years of age with transfusion-dependent β-thalassemia and a β0/β0, β0/β0-like, or non-β0/β0-like genotype. CD34+ HSPCs were edited by means of CRISPR-Cas9 with a guide mRNA. Before the exa-cel infusion, patients underwent myeloablative conditioning with pharmacokinetically dose-adjusted busulfan. The primary end point was transfusion independence, defined as a weighted average hemoglobin level of 9 g per deciliter or higher without red-cell transfusion for at least 12 consecutive months. Total and fetal hemoglobin concentrations and safety were also assessed. RESULTS: A total of 52 patients with transfusion-dependent β-thalassemia received exa-cel and were included in this prespecified interim analysis; the median follow-up was 20.4 months (range, 2.1 to 48.1). Neutrophils and platelets engrafted in each patient. Among the 35 patients with sufficient follow-up data for evaluation, transfusion independence occurred in 32 (91%; 95% confidence interval, 77 to 98; P<0.001 against the null hypothesis of a 50% response). During transfusion independence, the mean total hemoglobin level was 13.1 g per deciliter and the mean fetal hemoglobin level was 11.9 g per deciliter, and fetal hemoglobin had a pancellular distribution (≥94% of red cells). The safety profile of exa-cel was generally consistent with that of myeloablative busulfan conditioning and autologous HSPC transplantation. No deaths or cancers occurred. CONCLUSIONS: Treatment with exa-cel, preceded by myeloablation, resulted in transfusion independence in 91% of patients with transfusion-dependent β-thalassemia. (Supported by Vertex Pharmaceuticals and CRISPR Therapeutics; CLIMB THAL-111 ClinicalTrials.gov number, NCT03655678.).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Locatelli F, Lang P, Wall D, et al. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia. N Engl J Med. 2024. PMID: 38657265. doi:10.1056/NEJMoa2309673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。